Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death

Cancer Research

Volumn 66, Issue 7, 2006, Pages 3550-3557

  Hollmann, C Annette ^a,b   Owens, Trevor ^a   Nalbantoglu, Josephine ^a   Hudson, Thomas J ^b   Sladek, Robert ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CELL MARKER; RAG1 PROTEIN;

ARTICLE; B CELL LYMPHOMA; CELL DEATH; CELL MATURATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIGENS, CD40; APOPTOSIS; CELL LINE, TUMOR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; HUMANS; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); LYMPHOMA, B-CELL; LYMPHOMA, DIFFUSE; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-VAV;

EID: 33645745347     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2498     Document Type: Article

References (50)

1. 0van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67:2-17.
2. Uckun FM, Gajl-Peczalska K, Myers DE, Jaszcz W, Haissig S, Ledbetter JA. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 1990;76:2449-56.
3. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003;10:1-13.
4. Funakoshi S, Longo DL, Beckwith M, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994;83:2787-94.
5. Hirano A, Longo DL, Taub DD, et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999;93:2999-3007.
6. Vonderheide RH, Dutcher JP, Andersen JE, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 2001;19:3280-7.
7. Voorzanger-Rousselot N, Favrot M, Blay JY. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 1998;92:3381-7.
8. Buske C, Twiling A, Gogowski G, et al. In vitro activation of low-grade non-Hodgkin's lymphoma by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand. Leukemia 1997;11:1862-7.
9. Gerondakis S, Strasser A. The role of Rel/NF-κB transcription factors in B lymphocyte survival. Semin Immunol 2003;15:159-66.
10. Franklin RA, McCubrey JA. Kinases: positive and negative regulators of apoptosis. Leukemia 2000;14:2019-34.
11. Craxton A, Shu G, Graves JD, Saklatvala J, Krebs EG, Clark EA. p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes. J Immunol 1998;161:3225-36.
12. Gauld SB, Blair D, Moss CA, Reid SD, Harnett MM. Differential roles for extracellularly regulated kinase-mitogen-activated protein kinase in B cell antigen receptor-induced apoptosis and CD40-mediated rescue of WEHI-231 immature B cells. J Immunol 2002;168:3855-64.
13. Chang H, Blondal JA, Benchimol S, Minden MD, Messner HA. p53 mutations, c-myc, and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. Leuk Lymphoma 1995;19:165-71.
14. Epstein AL, Kaplan HS. Feeder layer and nutritional requirements for the establishment and cloning of human malignant lymphoma cell lines. Cancer Res 1979;39:1748-59.
15. Clark EA, Yip TC, Ledbetter JA, et al. CDw40 and BLCa-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes. Eur J Immunol 1988;18:451-7.
16. Hollmann AC, Gong Q, Owens T. CD40-mediated apoptosis in murine B-lymphoma lines containing mutated p53. Exp Cell Res 2002;280:201-11.
17. Hollmann CA, Kittrell FS, Medina D, Butel JS. Wnt-1 and int-2 mammary oncogene effects on the β-catenin pathway in immortalized mouse mammary epithelial cell lines are not sufficient for tumorigenesis. Oncogene 2001;20:7645-57.
18. Kurland JF, Voehringer DW, Meyn RE. The MEK/ERK pathway acts upstream of NF-κB1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line: MEK inhibition restores radiation-induced apoptosis. J Biol Chem 2003;278:32465-70.
19. Novak JP, Sladek R, Hudson TJ. Characterization of variability in large-scale gene expression data: implications for study design. Genomics 2002;79:104-13.
20. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93.
21. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279-84.
22. Donze O, Deng J, Curran J, Sladek R, Picard D, Sonenberg N. The protein kinase PKR: a molecular clock that sequentially activates survival and death programs. EMBO J 2004;23:564-71.
23. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002;18:207-8.
24. Karolchik D, Baertsch R, Diekhans M, et al. The UCSC Genome Browser Database. Nucleic Acids Res 2003;31:51-4.
25. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-86.
26. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403-10.
27. Von Knethen A, Abts H, Kube D, Diehl V, Tesch H. Expression of p56lck in B-cell neoplasias. Leuk Lymphoma 1997;26:551-62.
28. Grammer AC, Swantek JL, McFarland RD, Miura Y, Geppert T, Lipsky PE. TNF receptor-associated factor-3 signaling mediates activation of p38 and Jun N-terminal kinase, cytokine secretion, and Ig production following ligation of CD40 on human B cells. J Immunol 1998;161:1183-93.
29. Salojin KV, Zhang J, Delovitch TL. TCR and CD28 are coupled via ZAP-70 to the activation of the Vav/Rac-1-/PAK-1/p38 MAPK signaling pathway. J Immunol 1999;163:844-53.
30. Song JS, Haleem-Smith H, Arudchandran R, et al. Tyrosine phosphorylation of Vav stimulates IL-6 production in mast cells by a Rac/c-Jun N-terminal kinase-dependent pathway. J Immunol 1999;163:802-10.
31. Lin K, Abraham KM. Targets of p56 (lck) activity in immature thymoblasts: stimulation of the Ras/Raf/MAPK pathway. Int Immunol 1997;9:291-306.
32. Liu Y, Bishop A, Witucki L, et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 1999;6:671-8.
33. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-32.
34. Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoutos AG. inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J Biol Chem 2004;279:1010-9.
35. Perfetti V, Vignarelli MC, Bellotti V, et al. Membrane CD22 defines circulating myeloma-related cells as mature or later B cells. Lab Invest 1997;77:333-44.
36. Burrows PD, Cooper MD. B cell development and differentiation. Curr Opin Immunol 1997;9:239-44.
37. Williamson JM, Grigor I, Smith ME, et al. Cluster differentiation antigen expression, proliferative activity, and clinical stage in centroblastic centrocytic lymphomas. J Pathol 1986;150:51-9.
38. Shao N, Chai Y, Cui JQ, et al. Induction of apoptosis by Elk-1 and δElk-1 proteins. Oncogene 1998;17:527-32.
39. Wang YH, Nomura J, Faye-Petersen OM, Cooper MD. Surrogate light chain production during B cell differentiation: differential intracellular versus cell surface expression. J Immunol 1998;161:1132-9.
40. Tarlinton D. Germinal centers: a second childhood for lymphocytes. Curr Biol 1997;7:R155-9.
41. Zheng B, Fiumara P, Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003;102:1019-27.
42. Tanimoto Y, Kizaki H. Proteasome inhibitors block Ras/ERK signaling pathway resulting in the down-regulation of Fas ligand expression during activation-induced cell death in T cells. J Biochem (Tokyo) 2002;131:319-26.
43. Uckun FM, Schieven GL, Dibirdik I, Chandan-Langlie M, Tuel-Ahlgren L, Ledbetter JA. Stimulation of protein tyrosine phosphorylation, phosphoinositide turnover, and multiple previously unidentified serine/threonine-specific protein kinases by the Pan-B-cell receptor CD40/Bp50 at discrete developmental stages of human B-cell ontogeny. J Biol Chem 1991;266:17478-85.
44. Grass HJ, Herrmann F, Gattei V, Gloghini A, Pinto A, Carbone A. CD40/CD40 ligand interactions in normal, reactive, and malignant lympho-hematopoietic tissues. Leuk Lymphoma 1997;24:393-422.
45. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
46. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
47. Law CL, Gordon KA, Collier J, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005;65:8331-8.
48. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97:3361-9.
49. He H, Hirokawa Y, Levitzki A, Maruta H. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies. Cancer J 2000;6:243-8.
50. James JA, Smith MA, Court EL, et al. An investigation of the effects of the MEK inhibitor U0126 on apoptosis in acute leukemia. Hematol J 2003;4:427-32.